LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Upgraded by Freedom Capital

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by research analysts at Freedom Capital to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

LMAT has been the subject of a number of other research reports. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. Roth Mkm reiterated a “buy” rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Wells Fargo & Company raised their price objective on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research note on Thursday, February 26th. Finally, Citizens Jmp boosted their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $105.80.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $108.75 on Tuesday. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The stock’s 50 day moving average is $98.21 and its two-hundred day moving average is $90.43. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $115.33. The firm has a market capitalization of $2.48 billion, a PE ratio of 43.33, a P/E/G ratio of 3.14 and a beta of 0.67.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The business had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. During the same period in the prior year, the business posted $0.49 EPS. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insider Buying and Selling at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 55,930 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $107.81, for a total value of $6,029,813.30. Following the sale, the chief executive officer directly owned 1,476,500 shares in the company, valued at $159,181,465. The trade was a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David B. Roberts sold 8,464 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. The trade was a 32.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 215,438 shares of company stock valued at $23,062,911. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in the business. Cornerstone Planning Group LLC lifted its holdings in shares of LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 283 shares in the last quarter. MAI Capital Management purchased a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $38,000. First Horizon Corp acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth approximately $39,000. Geneos Wealth Management Inc. raised its position in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new stake in LeMaitre Vascular in the 2nd quarter valued at approximately $47,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.